RE:Debt is scary high and stock is expensive.First of all, it's hard to take somebody serious with the quality of grammar such as yours and with a name such as "drunk@noon." Secondly, I certainly don't see any calculations you speak of in your post that backs up your argument. Thirdly, you keep mentioning market cap when doing your "calculations." CXR and the healthcare sector in Canada has just suffered from an all-out short-selling attack that has brought it's market cap down 70%. The current market cap is temporary and will rebound quite quickly. How about you "re-calculate" in a couple months and then make the same argument. Fourthly, With a free cash flow of $400M, debt is easily manageable and will be paid down rapidly. Don't forget the estimated $600M revenue that will be generated from the 60 new drugs they will be rolling out. And lastly, you have ZERO credibility and respect in this board so just give up your game now and stop bashing CXR because nobody listens to what you say. The short-selling is over drunk@noon. Move on and finish that double rum with your lunch.
drunk@noon wrote: I am the only one who has posted calculations to back up arguement. EPS means very little bercause debt dwarfs market cap. You must add debt to market cap in caluclations. Educate yourself on this. And ebida means very little because of the hudge interest expense. Remember the I in Ebidta is interest expense. NOTICE how Rock07 misleads with using ebitda. And others post about EPS. Use expected cashflow. This is a highly leveraged company trading at high mulitiple of earnings to enterprise value with a low relitive growth rate. High single digits mean 9% or less annyalized growth. And that's if everything unfolds as management predicts. I have put forth caluculations to back this up. I would like to see the caluculations of these.